VEGFA and metastatic colorectal cancer: Recombinant humanized VEGF-A-specific monoclonal antibody, bevacizumab, was approved by the U.S. Food and Drug Administration (FDA) in 2004 for the first-line treatment of metastatic colorectal cancer (Hurwitz et al. 2004).